Trials / Completed
CompletedNCT00059657
Efficacy/Safety of Ecraprost in Lipid Emulsion for Treatment of Critical Leg Ischemia Due to Peripheral Arterial Disease
A Double-Blind, Randomized, Placebo-Controlled Study to Assess the Efficacy and Safety of CirculaseTM in Conjunction With Peripheral Revascularization for the Treatment of Critical Leg Ischemia
- Status
- Completed
- Phase
- Phase 3
- Study type
- Interventional
- Enrollment
- 280 (planned)
- Sponsor
- Tanabe Pharma Corporation · Industry
- Sex
- All
- Age
- 40 Years
- Healthy volunteers
- Not accepted
Summary
Ecraprost in lipid emulsion is being developed for the treatment of Critical leg ischemia (CLI), which is the most severe form of peripheral arterial disease (PAD); This trial is designed to assess the efficacy and safety of the drug in the treatment of CLI.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Ecraprost in lipid emulsion |
Timeline
- Start date
- 2001-08-01
- Completion
- 2005-11-01
- First posted
- 2003-05-02
- Last updated
- 2006-05-19
Locations
22 sites across 2 countries: United States, United Kingdom
Source: ClinicalTrials.gov record NCT00059657. Inclusion in this directory is not an endorsement.